Surgical choroidal neovascular membrane removal in the era of anti-vascular endothelial growth factor agents

March 2009
Indian Journal of Ophthalmology;Mar2009, Vol. 57 Issue 2, p146
Academic Journal
No abstract available.


Related Articles

  • Anti-VEGF therapy effective in choroidal neovascularization with choroidal osteoma.  // Ocular Surgery News;4/25/2013, Vol. 31 Issue 8, p16 

    The article discusses a research that suggests that choroidal neovascularization and retinal exudation in patients with choroidal osteoma can be regulated with anti-vascular endothelial growth factor (VEGF) therapy.

  • Injections for Wet AMD. Pewitt, Dawn // Review of Optometry;5/15/2004, Vol. 14 Issue 5, p104 

    Investigates how intravitreal injection may help treat choroidal neovascular membranes (CNVM) and possibly improve vision in wet age-related macular degeneration. Diagnosis of CNVM; Types of CNVM; Photodynamic therapy; Anti-vascular endothelial growth factor.

  • Choroidal neovascularization after intraocular foreign body. Fernández-López, Ester; Desco-Esteban, Mari Carmen; Fandiño-López, Adriana; Hernández-Díaz, Mikhail; Navea, Amparo // Clinical Ophthalmology;2014, Vol. 8, p945 

    We report an unusual case of choroidal neovascularization secondary to intraocular foreign body (IOFB) penetrating trauma. A 44-year-old man was referred to our department for IOFB trauma in the right eye. Vitrectomy and IOFB extraction was performed with good visual results. However, 2 months...

  • Anti-VEGF therapy effective in treatment of myopic CNV. Cimberle, Michela // Ocular Surgery News Europe;Jun2012, Vol. 23 Issue 6, p20 

    The article discusses a research study which showed the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in the treatment of patients with myopic choroidal neovascularization (CNV).

  • THE ABCS OF ANTI-VEGF. Ferrucci, Steven // Review of Optometry;11/15/2007 Supplement, Vol. 144, p12 

    The article focuses on the study on anti-vascular endothelial growth factor (anti-VEGF) as treatment option for other retinal diseases. Accordingly, VEGF plays a role in abnormal formation of blood vessels and vascular permeability. Macugen, lucentic and avastin are the anti-VEGF agents...

  • Inhibition of choroidal fibrovascular membrane formation by new class of RNA interference therapeutic agent targeting periostin. Nakama, T; Yoshida, S; Ishikawa, K; Kobayashi, Y; Zhou, Y; Nakao, S; Sassa, Y; Oshima, Y; Takao, K; Shimahara, A; Yoshikawa, K; Hamasaki, T; Ohgi, T; Hayashi, H; Matsuda, A; Kudo, A; Nozaki, M; Ogura, Y; Kuroda, M; Ishibashi, T // Gene Therapy;Feb2015, Vol. 22 Issue 2, p127 

    Age-related macular degeneration (AMD) is a vision-threatening disease characterized by choroidal fibrovascular membrane (FVM) formation, choroidal neovascularization (CNV) and choroidal fibrosis. No safe and effective therapeutic method has been developed for the choroidal fibrosis, although...

  • The Past, Present, and Future of Exudative Age-Related Macular Degeneration Treatment. Barak, Yoreh; Heroman, Wesley J.; Tezel, Tongalp H. // Middle East African Journal of Ophthalmology;Jan-Mar2012, Vol. 19 Issue 1, p43 

    Treatment of exudative age-related macular degeneration has been revolutionized within the last 6 years with the introduction of vascular endothelial growth factor neutralizing agents. Previously popular "destructive treatments," such as laser photocoagulation and photodynamic treatment have...

  • CNV lesions show regression. Charters, Lynda; Cousins, Scott // Ophthalmology Times;11/15/2009, Vol. 34 Issue 22, p29 

    The article features the study made by Dr. Scott Cousins on the efficacy of E10030 anti-platelet-derived growth factor (PDGF) from Ophthotech Corp. and Lucentis anti-vascular endothelial growth factor (VEGF) agent from Genentech Inc. in Fort Lauderdale, Florida. With the combination of PDGF and...

  • Anti-VEGF Therapy to Treat Corneal Neovascularization. Papathanassiou, M.; Theodoropoulou, S.; Analitis, S.; Tzonou, A. // Review of Ophthalmology;Jun2013, Vol. 20 Issue 6, p77 

    The article discusses the role of anti-vascular endothelial growth factor (VEGF) therapy in treatment of corneal neovascularization.

  • ANTI-VEGF THERAPY: SETTING A NEW STANDARD FOR AMD TREATMENT. D'Amico, Donald J.; Packo, Kirk H. // Ophthalmology Times;8/1/2005 Supplement, Vol. 30, p3 

    Highlights developments in the treatment of wet age-related macular degeneration with anti-vascular endothelial growth factor (VEGF) therapy. Ability of VEGF to increase vascular permeability; Approval of pegaptanib for the treatment of all angiographic subtypes; Role of (VEGF) in choroidal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics